Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Other 1Gynecologic 1

Conditions

Endometrial Neoplasms 5Overweight 2Obesity 2Neoplasms 2Endometrial Hyperplasia 2Infertility 1Hematologic Neoplasms 1FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1Breast Neoplasms 1Anorexia 1

Interventions

pembrolizumab 36Bevacizumab 25Cyclophosphamide 22Blood Specimen Collection 18Nivolumab 17Carboplatin 15Standard of Care 14Paclitaxel 14atezolizumab 13Gemcitabine 13Exercise 13Pemetrexed 11Fluorouracil 11Doxorubicin 11Cisplatin 11Cetuximab 10Radiotherapy 9Oxaliplatin 9Magnetic Resonance Spectroscopy 9Leucovorin 9Docetaxel 9durvalumab 8abemaciclib 8Temozolomide 8Surveys and Questionnaires 8Rituximab 8Prednisone 8Biopsy 8130-nm albumin-bound paclitaxel 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Megestrol Acetate × 90 days × Clear all
NCT06979596 2026-05-13

OMAHA-015

Merck Sharp & Dohme LLC

Phase 2 Recruiting
250 enrolled
Tumor-Agnostic

Neoplasms

NCT07462663 2026-05-13

SHAPE-ENDO

Hospital Universitari de Bellvitge

Phase 4 Not yet recruiting
82 enrolled
GynecologicOther

Endometrial Hyperplasia, Neoplasms, Obesity, Endometrial Neoplasms, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon âš¡